Lucid Genomics Named PacBio Compatibility Partner for Secondary and Tertiary Analysis
Collaboration positions Lucid Genomics as a compatible solution for long-read genomic data analysis to support clinicians and researchers within the PacBio ecosystem
Berlin, April 14th — Lucid Genomics GmbH, a leading provider of bioinformatics software for clinical and research genomics, today announced that it has been designated as a Compatibility Partner by PacBio (Pacific Biosciences of California, Inc.), a premier developer of sequencing solutions. Under this designation, Lucid Genomics is recognized as a compatible platform for secondary and tertiary analysis of data generated on PacBio long-read sequencing instruments.
The designation highlights the interoperability of Lucid Genomics’ analysis platform with PacBio’s HiFi sequencing technology, enabling researchers and clinicians to transform raw sequencing data into meaningful genomic insights. From base-level variant calling and structural variant detection to comprehensive clinical interpretation and reporting, Lucid Genomics delivers a unified workflow optimized for the accuracy and throughput of PacBio sequencing.
Compatibility Built on Performance and Precision
PacBio’s Compatibility Partner Program recognizes third-party software and services providers whose solutions have been validated to work seamlessly with PacBio instruments and data formats. As a named partner, Lucid Genomics joins a group of organizations recognized for compatibility with PacBio systems and data formats, supporting high-quality downstream analysis of PacBio long-read sequencing data.
Lucid Genomics’ platform supports the full spectrum of analysis tasks, including alignment, phasing, variant annotation, methylation analysis, and clinical-grade reporting, all purpose-built to leverage the high fidelity and long-range information unique to PacBio HiFi reads. The integration enables laboratories of all sizes to adopt a streamlined, validated pipeline from sequencer to clinical or research report.
“Being recognized as a PacBio Compatibility Partner is a significant milestone for Lucid Genomics and for our customers. Long-read sequencing is unlocking parts of the genome that were simply invisible before: non-coding regions, methylation patterns, structural variants in the dark genome. Lucid was built from the ground up as a long-read native company to extract exactly this kind of diagnostic value. This designation gives our users confidence they are working with a solution that is tested, trusted, and purpose-fit for PacBio sequencing."
— Dr. Uira Souto Melo, Founder & CEO, Lucid Genomics
Expanded Access to Validated Long-Read Workflows
For laboratories and research institutions running PacBio instruments, the collaboration provides a clear path to compatible, production-ready secondary and tertiary analysis. Users can access Lucid Genomics’ cloud-native platform with confidence that workflows have been assessed for compatibility with PacBio data standards, reducing integration risk and accelerating time-to-insight.
Lucid Genomics and PacBio may collaborate on joint customer engagements, technical enablement resources, and co-marketing initiatives to support the growing community of long-read sequencing users worldwide.
For more information about Lucid Genomics and its integration with PacBio sequencing platforms, visit www.lucid-genomics.com or contact the Lucid Genomics team directly.
About Lucid Genomics
Lucid Genomics is a bioinformatics company dedicated to making genomic data analysis faster, more accurate, and more accessible. The company’s cloud-native platform supports secondary and tertiary analysis for clinical laboratories, research institutions, and biotechnology companies working with next-generation and long-read sequencing technologies.
About PacBio
PacBio (Nasdaq: PACB) is a premier life science technology company that enables the most accurate genomic and epigenomic insights with its industry-leading sequencing platforms. Powered by its proprietary HiFi sequencing technology, PacBio systems deliver highly accurate long reads that are transforming our understanding of genomes and empowering researchers and clinicians to make new discoveries and develop new treatments for disease.
Media Contact
Lucid Genomics Communications